신규한 퓨린 유도체 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
    23.
    发明公开
    신규한 퓨린 유도체 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 有权
    新型嘌呤衍生物和组合物,用于预防或治疗含有其的癌症

    公开(公告)号:KR1020160039870A

    公开(公告)日:2016-04-12

    申请号:KR1020140133134

    申请日:2014-10-02

    CPC classification number: C07D473/18 A61K31/52 C07D401/06

    Abstract: 본발명은암세포에대한우수한항증식효능을나타내는퓨린화합물, 이의약학적으로허용가능한염, 또는수화물과, 이의제조방법및 이를유효성분으로함유하는암 전이및 증식성질환의예방또는치료용의약조성물, 및암세포에대한항암조성물에관한것으로서, 상기본 발명에따른화합물, 이의약학적으로허용가능한염, 또는수화물은낮은세포독성을보이면서우수한암세포억제활성및 항증식효능을나타내므로, 암세포저해는물론이고나아가암 전이및 증식성질환의예방또는암 치료에유용하게사용될수 있다.

    Abstract translation: 本发明涉及对癌细胞表现出优异的抗增殖作用的嘌呤化合物,其药学上可接受的盐或水合物,其制备方法,包含其作为预防或治疗癌症转移和增殖性疾病的活性成分的药物组合物 ,以及对癌细胞有效的抗癌成分。 根据本发明,化合物及其药学上可接受的盐或水合物在显示出优异的癌细胞抑制活性和抗增殖作用的同时表现出低细胞毒性,因此可用于抑制癌细胞和预防或治疗癌症转移或增殖 疾病。 本发明的嘌呤化合物由化学式1表示。

    5-HT7 수용체에 작용하는 카바졸 유도체
    24.
    发明公开
    5-HT7 수용체에 작용하는 카바졸 유도체 有权
    在5-HT7受体上起作用的卡博唑衍生物

    公开(公告)号:KR1020150121897A

    公开(公告)日:2015-10-30

    申请号:KR1020140048074

    申请日:2014-04-22

    CPC classification number: C07D209/82 A61K31/33 A61K31/403 C07D209/80

    Abstract: 본발명은 5-HT수용체에작용하는카바졸유도체및 이의약제학적으로허용가능한염에관한것으로, 5-HT세로토닌수용체에대하여우수한결합친화력과우수한길항활성을가져 5-HT길항활성이요구되는우울증, 편두통, 불안, 통증, 염증성통증, 신경병성통증, 체온조절장애, 생체리듬조절장애, 수면장애및 평활근관련질환등의중추신경계질환의치료및 예방제로유용하게적용할수 있다.

    Abstract translation: 本发明涉及作用于5-HT_7受体的咔唑衍生物及其药学上可接受的盐,其中5-HT_7受体具有优异的结合亲和力和优异的拮抗活性,因此可用于应用于治疗和预防中枢的药剂 神经系统疾病如重症抑郁障碍,偏头痛,焦虑症,疼痛,炎症性疼痛,神经性疼痛,温度调节障碍,昼夜节律调节障碍,睡眠障碍和平滑肌相关疾病等,需要5-HT_7拮抗活性。

    항균활성을 갖는 신규 이중고리를 포함하는 옥사졸리디논 유도체 및 이의 제조방법
    26.
    发明公开
    항균활성을 갖는 신규 이중고리를 포함하는 옥사졸리디논 유도체 및 이의 제조방법 有权
    含有新型双组分的具有抗菌活性的氧杂环丁酮衍生物及其制备方法

    公开(公告)号:KR1020130006554A

    公开(公告)日:2013-01-17

    申请号:KR1020110066569

    申请日:2011-07-05

    Abstract: PURPOSE: AN oxazolidinone derivative containing a novel cyclic group is provided to ensure excellent antibacterial activity against gram-positive bacteria including various resistant strains. CONSTITUTION: An oxazolidionone derivative containing a cyclopenta[c]pyloriphenyl group is denoted by chemical formula 1. An antibacterial composition contains the oxazolidinone derivative or a pharmaceutically acceptable salt thereof as an active ingredient. The antibacterial composition has antibacterial activity against Staphylococcus sp., Enterococcus sp., E.coli, Bacillus sp., Salmonella sp. or Mycobacterium.

    Abstract translation: 目的:提供含有新环状基团的恶唑烷酮衍生物,以确保对包括各种抗性菌株在内的革兰氏阳性菌具有优异的抗菌活性。 构成:含有环戊二烯并[c]苯乙烯基的恶唑烷酮衍生物由化学式1表示。抗菌组合物含有恶唑烷酮衍生物或其药学上可接受的盐作为活性成分。 抗菌组合物对葡萄球菌属,肠球菌属,肠杆菌属,大肠杆菌属,芽孢杆菌属,沙门氏菌属, 或分枝杆菌。

    T-형 칼슘 채널 길항제로서의 5-(치환된알킬아미노메틸)아이속사졸계 화합물
    27.
    发明公开
    T-형 칼슘 채널 길항제로서의 5-(치환된알킬아미노메틸)아이속사졸계 화합물 有权
    5-(取代的烷基氨基甲酰基)异噻唑衍生物作为T型钙通道拮抗剂

    公开(公告)号:KR1020120096842A

    公开(公告)日:2012-08-31

    申请号:KR1020110016203

    申请日:2011-02-23

    CPC classification number: C07D413/12

    Abstract: PURPOSE: A 5-(substituted alkylaminomethyl)isoxazole based compound as T-type calcium channel blocker is provided to have excellent activity as an antagonist of T- type calcium ion channel. CONSTITUTION: A 5-(substituted alkylaminomethyl)isoxazole based compound as T-type calcium channel blocker is represented by chemical formula 1. The encephalopathy therapy and for prevention agent selected from epilepsy, depression, Parkinson's disease, dementia, sleep disorder, an agent for cancer treatment and prevention, an agent for heart disease treatment and prevention selected from hypertensive, cardiac arrhythmia, angina, myocardial infarction, congestive heart failure, pharmaceutical composition for alleviating pain selected from neuropathic pain and chronic and acute pain includes a compound represented by chemical formula 1.

    Abstract translation: 目的:提供作为T型钙通道阻滞剂的5-(取代的烷基氨基甲基)异恶唑基化合物作为T-型钙离子通道的拮抗剂具有优异的活性。 构成:以化学式1表示作为T型钙通道阻断剂的5-(取代烷基氨基甲基)异恶唑类化合物。脑病治疗和预防药物选自癫痫,抑郁症,帕金森病,痴呆,睡眠障碍, 癌症治疗和预防,选自高血压,心律失常,心绞痛,心肌梗塞,充血性心力衰竭,减轻选自神经性疼痛和慢性和急性疼痛的疼痛的药物组合物的心脏病治疗和预防剂,包括由化学式 1。

    T-형 칼슘 채널에 활성을 지닌 신규 옥사졸-피페라진 유도체 및 이의 제조방법
    29.
    发明公开
    T-형 칼슘 채널에 활성을 지닌 신규 옥사졸-피페라진 유도체 및 이의 제조방법 有权
    具有T型钙通道活性的新型奥氮唑 - 哌嗪化合物

    公开(公告)号:KR1020110020023A

    公开(公告)日:2011-03-02

    申请号:KR1020090077687

    申请日:2009-08-21

    Abstract: PURPOSE: An oxazole-piperazine compound having a pharmaceutical activity with respect to T-type calcium channel is provided to ensure excellent activity as an antagonist of the channel and to prevent and treat cancer, epilepsy, heart diseases, and pain. CONSTITUTION: An oxazole-piperazine compounds is denoted by chemical formula 1. A pharmaceutical composition for treating epilepsy, cancer, hypertension, myocardial infarction, neuropathic pain, and acute and chronic pain contains the oxazole-piperazine compound of chemical formula 1. The compound of chemical formula 1 is prepared by reacting piperazine-amine compound of chemical formula 2 and oxazole aldehyde compound of chemical formula 3 by reductive amination. The reductive amination is performed under the presence of molecules of 4-8 meshes and NaBH(OAc)_3, NaBH_3CN, or NaBH_4.

    Abstract translation: 目的:提供相对于T型钙通道具有药学活性的恶唑 - 哌嗪化合物,以确保作为通道拮抗剂的优异活性,并预防和治疗癌症,癫痫,心脏病和疼痛。 构成:化学式1表示恶唑 - 哌嗪化合物。用于治疗癫痫,癌症,高血压,心肌梗死,神经性疼痛和急性和慢性疼痛的药物组合物含有化学式1的恶唑 - 哌嗪化合物。 化学式1通过化学式2的哌嗪 - 胺化合物和化学式3的恶唑醛化合物通过还原胺化反应来制备。 还原胺化在4-8目和NaBH(OAc)3,NaBH 3 CN或NaBH 4的分子存在下进行。

    무스카린성 아세틸콜린 수용체에 작용하는테트라하이드로피리딘 유도체
    30.
    发明授权
    무스카린성 아세틸콜린 수용체에 작용하는테트라하이드로피리딘 유도체 失效
    무스카린성아세틸콜린수용체체에용하는테트라하이드로피리딘유도체

    公开(公告)号:KR100432283B1

    公开(公告)日:2004-05-22

    申请号:KR1020010066568

    申请日:2001-10-27

    CPC classification number: C07D401/06

    Abstract: The present invention relates to novel tetrahydropyridine derivatives of formula 1 having an appropriately substituted pyrrolidinone and oxime, wherein m is 0 or 1, n is 1 or 2, R1 is hydrogen, C1-4 alkyl, C2-4 alkynyl or aryl, R3 is C1-4 alkyl, which show high efficacy, low cholinergic adverse effects and high affinity for muscarinic acetylcholine receptor; and pharmaceutically acceptable salts thereof; processes for the preparation thereof; and pharmaceutical compositions comprising these compounds or salts.

    Abstract translation: 本发明涉及具有适当取代的吡咯烷酮和肟的式1的四氢吡啶衍生物,其中m为0或1,n为1或2,R 1为氢,C 1-4烷基,C 2-4炔基或芳基,R 3为 它表现出高效力,低胆碱能不良作用和对毒蕈碱乙酰胆碱受体的高亲和力; 和其药学上可接受的盐; 其制备方法; 和包含这些化合物或盐的药物组合物。

Patent Agency Ranking